{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:34:36Z","timestamp":1777419276696,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,10,4]],"date-time":"2002-10-04T00:00:00Z","timestamp":1033689600000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> We performed a prospective pilot study on 12 patients to evaluate the efficacy of the anti\u2010CD20 monoclonal antibody rituximab in relapsed idiopathic thrombocytopenic purpura (ITP). Inclusion criteria were relapse of ITP with a thrombocyte count &lt;20\u2003000\u2003\u00b5L<jats:sup>\u22121<\/jats:sup> and unsuccessful corticosteroid treatment. Eleven patients had a previous splenectomy, five patients had unsuccessful cytotoxic treatment, and six patients were refractory to intravenous immunoglobulins before rituximab therapy. Response criteria were as follows. Complete remission (CR): normalization of thrombocyte count for at least 30\u2003d. Partial remission (PR): an increase of thrombocytes to above 30\u2003000\u2003\u00b5L<jats:sup>\u22121<\/jats:sup> for at least 30\u2003d. Minor response (MR): any increase above 30\u2003000\u2003\u00b5L<jats:sup>\u22121<\/jats:sup> for less than 30\u2003d but more than 10\u2003d. No response (NR): failure to achieve any of the above responses. Treatment plan: We administered 375\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup> of rituximab once weekly on up to four consecutive weeks, unless there was early CR. Five patients (41%) achieved CR, two patients (17%) PR, and two patients MR (overall response rate 75%, median follow\u2010up of responders 320\u2003d). Four CR patients are ongoing; one CR patient relapsed after 6\u2003months. Adverse events included excessive thrombocytosis in one patient as well as minor infusion\u2010related (grade I) toxicities in four patients. We conclude that rituximab is a promising agent in the treatment of relapsed ITP.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.02686.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:28Z","timestamp":1047408808000},"page":"95-100","source":"Crossref","is-referenced-by-count":88,"title":["Treatment of relapsed idiopathic thrombocytopenic purpura with the anti\u2010CD20 monoclonal antibody rituximab: a pilot study"],"prefix":"10.1111","volume":"69","author":[{"given":"A.A.N.","family":"Giagounidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Anhuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"S\u00f6hngen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Quabeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,4]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)12118-8"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90107-0"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.2.351.351"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04810.x"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02569.x"},{"key":"e_1_2_14_7_2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood.V81.12.3484.3484","article-title":"Combination chemotherapy in refractory immune thrombocytopenic purpura","volume":"81","author":"Figueroa M","year":"1993","journal-title":"Blood"},{"key":"e_1_2_14_8_2","first-page":"91","article-title":"Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients","volume":"27","author":"Bussel JB","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.952"},{"key":"e_1_2_14_10_2","first-page":"14a","article-title":"Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura [abstract]","volume":"94","author":"Perotta A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2549"},{"key":"e_1_2_14_12_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC\u2010C2B8 (Rituximab) anti\u2010CD20 monoclonal antibody therapy in patients with relapsed low\u2010grade non\u2010Hodgkin\u00eds lymphoma","volume":"80","author":"Maloney DG","year":"1997","journal-title":"Blood"},{"key":"e_1_2_14_13_2","first-page":"1201","article-title":"Vaccination after splenectomy and in asplenia","volume":"39","author":"Germing U","year":"1998","journal-title":"Internist"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02686.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02686.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.02686.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:44:17Z","timestamp":1697550257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.02686.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1034\/j.1600-0609.2002.02686.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.02686.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}